Drugs / ADP-597
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01054118 | Dec 2009 → Feb 2010 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00946972 | Jul → Nov 2009 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | No outcome recorded |
| Phase 1 | NCT00871507 | Apr → Jul 2009 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00910923 | Nov 2008 → Apr 2009 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADP-597 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1951032 ↗ |
| Known as | JNJ-38431055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01054118 ↗ |
| Modality | Small molecule | — CHEMBL1951032 ↗ |
| Route | Oral | “Study drug will be administered as single oral doses separated by at least 7 days.” NCT00871507 ↗ |